Synopsis: Fortis Healthcare Limited is rated “Buy” by Citigroup, with strong growth expected, improving margins, and possible parent support, despite a temporary impact on international patients.
This Mid-cap Healthcare Stock, engaged in providing hospital, diagnostic, and healthcare services, delivering quality medical care through its network of hospitals and skilled professionals across India, is in focus after Citi gave a Buy target of Rs. 1,210, which has an upside potential of 44 percent.
With a market capitalization of Rs. 59,000 crore, the shares of Fortis Healthcare Limitedare currently trading at Rs. 780 per equity share, down nearly 1.15 percent from its previous day’s close price of Rs. 788.80.
What is the News?
Citi, a prominent brokerage firm, has recommended a “Buy” call on Fortis Healthcare Limited with a target price of Rs. 1,120 per share, indicating an upside potential of 44 percent from its current price of Rs. 780 per share.
Fortis Healthcare Limited continues to receive a Buy rating from Citigroup, reflecting confidence in its long-term growth. While disruptions in the Middle East have impacted international patient inflows, this is expected to be temporary as travel conditions improve over time.
The company has guided for hospital EBITDA margins of around 22 percent in FY26, showing stable operational performance. As efficiency improves and patient volumes recover, margins are expected to gradually rise to 24-25 percent, supporting stronger profitability.
Additionally, its parent, IHH Healthcare, may increase its stake through equity infusion or consolidation. This could strengthen financial stability and support future expansion, making the overall outlook positive.
Business Highlights:
Fortis Healthcare Limited is a large healthcare provider with 36 facilities that offer medical services to many people. It has over 6,000 operational beds, showing its strong capacity to care for patients. The organization focuses on providing quality treatment and improving health services across its locations.
It also has a strong team of around 7,600 doctors and 9,400 nurses, supported by about 28,000 employees. This large workforce helps ensure patients receive proper care and attention. Overall, the company plays an important role in delivering reliable and accessible healthcare.
Revenue Mix (Q3 FY25):
Fortis Healthcare Limited’s quarterly revenue comes from different regions, with South India contributing the highest share at 34 percent. North follows with 29 percent, while West and East contribute 20 percent and 12 percent, respectively. International business makes up a smaller portion at 5 percent, showing the company is mainly focused on domestic markets.
In terms of product mix, routine healthcare generates the largest share of revenue at 53 percent. Specialised services contribute 35 percent, while wellness services add 12 percent. This shows the company earns most from regular treatments but also benefits from advanced and preventive care.
Company Overview:
Fortis Healthcare Limited was founded in 1996 and is a leading integrated healthcare services company headquartered in Mohali, Punjab, India. It operates one of the country’s largest private hospital networks, providing multi-specialty medical care across India, the United Arab Emirates, and Sri Lanka. The firm is a subsidiary of IHH Healthcare Berhad, a global healthcare group based in Malaysia.
Recent Quarter Results:
Coming into financial highlights, Fortis Healthcare Limited’s revenue has increased from Rs. 1,928 crore in Q3 FY25 to Rs. 2,265 crore in Q3 FY26, which has grown by 17.48 percent. The net profit has decreased by 22.44 percent from Rs. 254 crore in Q3 FY25 to Rs. 197 crore in Q3 FY26.
Fortis Healthcare Limited’s revenue and net profit have grown at a CAGR of 10.94 percent and 54.8 percent, respectively, over the last five years.
In terms of return ratios, the company’s ROCE and ROE stand at 12.0 percent and 10.1 percent, respectively. Fortis Healthcare Limited has an earnings per share (EPS) of Rs. 12.7, and its debt-to-equity ratio is 0.34x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Can Fortis Healthcare’s improving margins and patient recovery drive future share price growth? appeared first on Trade Brains.
Original Article
(Disclaimer – This post is auto-fetched from publicly available RSS feeds. Original source: Tradebrains. All rights belong to the respective publisher.)
